Midway University

Recent papers from Midway University

1. Artificial intelligence in breast cancer research: a systematic review and bibliometric analysis of emerging trends and future directionsFrontiers in Oncology · 2026
2. Digital Twins for Hospital and Healthcare Operations: A Systematic Review of Resource Allocation, Infection Control, and Workflow OptimizationBioengineering · 2026
3. Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021–2024Infectious Diseases and Therapy · 2026
4. Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare NetworkJAIDS Journal of Acquired Immune Deficiency Syndromes · 2026
5. End-to-End Intelligent Drug Discovery via a Scalable and Explainable Graph-Transformer FrameworkBioengineering · 2026
6. Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 TreatmentNew England Journal of Medicine · 2026
7. People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesAIDS Patient Care and STDs · 2026
8. 1496-P: Perceived Diabetes Risk and Provider Risk Communication Based on Polycystic Ovary Syndrome StatusDiabetes · 2026
9. How well do you know the patient standing before you?Prosthetics and Orthotics International · 2026
10. The Impact of Instructional Guidance on Science Learning in Second-Grade ClassroomsThe Elementary School Journal · 2026
11. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialThe Lancet · 2026
12. Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialThe Lancet · 2026
13. FibroidX: Vision Transformer-Powered Prognosis and Recurrence Prediction for Uterine Fibroids Using Ultrasound ImagesCancers · 2026
14. P-377. Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1Open Forum Infectious Diseases · 2026
15. Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical TrialDrugs in R&D · 2025
16. Prompt-Driven Multimodal Segmentation with Dynamic Fusion for Adaptive and Robust Medical Imaging with Applications to Cancer DiagnosisCancers · 2025
17. Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyNature Medicine · 2025
18. Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at BaselineOpen Forum Infectious Diseases · 2025
19. Identifying Factors Associated With HIV Viral Suppression and Health Care Outcomes in the Florida Cohort Study Wave 3: Protocol for a Prospective Cohort Study.2025
20. Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyAIDS Research and Therapy · 2025